Merck KGaA (MKGAF ) recently presented detailed results on its oncology candidate L-BLP25, from the phase III study, START...
Merck KGaA (MKGAF) reported first quarter 2013 earnings per American Depositary Receipt (ADR) of $2.79, up 28.1% year over year. Revenues for...
Merck KGaA (MKGAF) and Columbia Laboratories, Inc. (CBRX) recently renewed a license and supply agreement for Crinone (progesterone gel...
Sanofi’s (SNY) subsidiary, Genzyme, recently announced interim data on its multiple sclerosis (MS) candidate, Lemtrada (alemtuzumab), from...
Merck KGaA (MKGAF) recently announced a deal with Bristol-Myers Squibb (BMY) for the promotion of different formulations of Glucophage...
Merck KGaA (MKGAF) recently announced a strategic deal with Nordic Bioscience Clinical Development A/S for its pipeline candidate, sprifermin...
Threshold Pharmaceuticals Inc. (THLD) reported fourth-quarter 2012 net loss per share of 10 cents, narrower than the Zacks Consensus Estimate of...
Merck KGaA (MKGAF) reported fourth quarter 2012 earnings per American Depository Receipt (ADR) of $2.66, up 18.8% year over year. Revenues...
BioMarin Pharmaceutical Inc. (BMRN) recently announced positive results from the PKU-016 ASCEND study. This is the largest randomized controlled...
Threshold Pharmaceuticals, Inc. (THLD) and Merck KGaA (MKGAF) recently announced the commencement of a global phase III study (MAESTRO) on their...
Sanofi’s (SNY) subsidiary, Genzyme, recently announced that the US Food and Drug Administration (FDA) has accepted the marketing...
BioMarin Pharmaceutical Inc. (BMRN) recently reported positive results from the much awaited phase III study (MOR-004) of GALNS (2mg/kg) for the...
Merck Serono, the biopharmaceutical division of Merck KGaA (MKGAF), announced the creation of a new company, Asceneuron. Asceneuron is the third...
BioMarin Pharmaceutical Inc. (BMRN) recently announced preliminary results from a phase II program of PEG-PAL (PEGylated recombinant...
Cumberland Pharmaceuticals Inc. (CPIX) recently announced encouraging top-line results from a phase IV study on Caldolor (the intravenous...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
News
Market Data
Register for real-time alerts, custom portfolio, and market movers
